ATXI

NASDAQ

Avenue Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2017

News25/Ratings0

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

News · 26 weeks13+100%

2025-10-262026-04-19

Mix390d

SEC Filings2(67%)
Other1(33%)

Latest news

25 items

24dSEC
SEC Form 10-K filed by Avenue Therapeutics Inc.
10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
59dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
59dPR
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d
107dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
107dINSIDER
Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
113dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
128dSEC
SEC Form EFFECT filed by Avenue Therapeutics Inc.
EFFECT - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
129dSEC
SEC Form POS AM filed by Avenue Therapeutics Inc.
POS AM - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
129dSEC
SEC Form RW filed by Avenue Therapeutics Inc.
RW - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
139dSEC
SEC Form DEF 14A filed by Avenue Therapeutics Inc.
DEF 14A - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
156dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
161dSEC
SEC Form 10-Q filed by Avenue Therapeutics Inc.
10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
162dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
252dSEC
SEC Form 10-Q filed by Avenue Therapeutics Inc.
10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
279dSEC
SEC Form 25-NSE filed by Avenue Therapeutics Inc.
25-NSE - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
343dSEC
SEC Form 10-Q filed by Avenue Therapeutics Inc.
10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
358dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
386dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
386dINSIDER
Large owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
388dSEC
SEC Form 10-K filed by Avenue Therapeutics Inc.
10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
402dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
412dSEC
Avenue Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
433dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Avenue Therapeutics Inc.
SCHEDULE 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
475dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
475dINSIDER
New insider Fortress Biotech, Inc. claimed ownership of 294,800 shares (SEC Form 3)
3 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)